Your browser does not support java script. Skip navigation
Loading, please wait  Loading, please wait...
 
 

SCSHP Annual Meeting 2020 (Pharmacists)


SCSHP 2020 Annual Meeting
Thursday, March 12 - Friday March 13, 2020
 
To register and view the full meeting agenda, visit https://www.scshp.com/events/EventDetails.aspx?id=1254736
For information on the Directors/Managers Workshop Click Here!
 
Location:  North Charleston Marriott, 4770 Goer Drive North Charleston, South Carolina 29406 
 
For all continuing education session details, including speakers and learning objectives, please expand the individual sessions below! 

Date: Mar 12, 2020 08:00 AM - Mar 13, 2020 05:45 PM

Fee

$0.00

CE Hours

15.00

CE Units

1.500

Activity Type

  • Knowledge-Based and Application-Based

Target Audience(s)

  • Pharmacists

Accreditation(s)

Accreditation Council for Pharmacy Education
The University of South Carolina College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Co-Sponsor(s)

SCSHP

Requirements for CE Credit

In order to claim credit and have CE credit submitted to the CPE Monitor, participants must complete the following steps within 60 days of the event.  Completion of these steps within 30 days of the event will allow for any issues in transmission to NABP to be rectified by our office. The CPE Monitor will not accept credit that is submitted greater than 60 days after the event per NABP policy.
  1. Check in upon arrival at the meeting
  2. Complete and submit the "CE Sign In" form at the meeting
  3. Complete the online program evaluations
  4. Provide the correct month and day of birth and NABP e-Profile ID.  Registration with a proper disclosure of your NABP E-Profile ID is a requirement for receiving Continuing Pharmacy Education.  To register with or look up your NABP e-Profile ID, please click on the CPE Monitor logo below to be directed to their site.  

 

 

 

 

At the completion of this activity, the pharmacist will be able to:
  1. Define burnout, well-being, and resilience
  2. Explain why clinician burnout is a patient care and healthcare workforce problem
  3. Discuss the U.S. National Academy of Medicine Clinician Well-Being and Resilience Action Collaborative and consensus study
  4. Identify strategies to improve well-being and resilience in the healthcare workforce

Speaker(s)/Author(s)

Paul W. Abramowitz, Pharm.D., Sc.D. (Hon), FASHP
Chief Executive Officer, ASHP

Activity Number

0062-9999-20-084-L04-P
Date: 03/12/20
Time: 08:00 AM - 09:00 AM

CE Hours

1.00
 

 

At the completion of this activity, the pharmacist will be able to:
  1. Recognize that diversity promotes healthier leadership and decision-making
  2. Define implicit biases and their pervasiveness
  3. Examine the impact of mitigating implicit bias on decisions in healthcare and education

Speaker(s)/Author(s)

B. DaNine Fleming, EdS, EdD
Associate Professor, Director of Training and Intercultural Education, and Unconscious Bias Faculty Scholar, MUSC

Activity Number

0062-9999-20-085-L04-P
Date: 03/12/20
Time: 09:00 AM - 10:00 AM

CE Hours

1.00
 

 

At the completion of this activity, the pharmacist will be able to:
  1. Apply updated infectious diseases treatment guidelines and policies to antimicrobial recommendations
  2. Analyze clinical implications of peer-reviewed infectious diseases literature
  3. Determine the role of newly approved antimicrobials
  4. Acknowledge emerging pathogens both nationally and globally
  5. Discuss changes in roles and responsibilities of pharmacists in managing infectious diseases

Speaker(s)/Author(s)

P. Brandon Bookstaver, PharmD, FCCP, FIDSA, BCPS
Associate Professor and Director of Residency & Fellowship Training, University of South Carolina College of Pharmacy; Infectious Diseases PGY2 & Clinical Fellowship Director, Prisma Health Richland

Activity Number

0062-9999-20-086-L01-P
Date: 03/12/20
Time: 10:30 AM - 11:30 AM

CE Hours

1.00
 

 

At the completion of this activity, the pharmacist will be able to:
  1. Identify patients who would be appropriate candidates for high-dose intravenous thiamine replacement
  2. Recognize when a short-course corticosteroid regimen may require a taper
  3. Explain the unreliability of subgroup analyses

Speaker(s)/Author(s)

Kathryn Rice, PharmD, BCPS
Assistant Professor of Pharmacy Practice, South University School of Pharmacy

Activity Number

0062-9999-20-087-L01-P
Date: 03/12/20
Time: 11:30 AM - 01:00 PM

CE Hours

1.50
 

 

At the completion of this activity, the pharmacist will be able to:
  1. Explain the mechanism of action for sodium glucose co-transporter 2 (SGLT-2) inhibitors
  2. Critically evaluate the published literature regarding SGLT-2 inhibitors on heart failure (HF) outcomes
  3. Formulate a treatment regimen with a SGLT-2 inhibitor for a patient with type 2 diabetes mellitus (T2DM) and HF

Speaker(s)/Author(s)

Jennifer Clements, PharmD, FCCP, BCPS, CDE, BCACP
Clinical Pharmacist - Diabetes Transition, Spartanburg Regional Healthcare System

Activity Number

0062-9999-20-088-L01-P
Date: 03/12/20
Time: 01:30 PM - 02:30 PM

CE Hours

1.00
 

 

At the completion of this activity, the pharmacist will be able to:
  1. Recall pharmacy trivia related to pharmacology, pharmacokinetics, pharmacodynamics, pharmacogenomics, clinical pharmacy history, biostatistics, and health outcomes
  2. Summarize clinical knowledge in response to a case vignette using supporting laboratory, physical examination, and medical history information
  3. Discuss numerous drug therapy and specialty areas through response to pharmacotherapy questions

Speaker(s)/Author(s)

P. Brandon Bookstaver, PharmD, FCCP, FIDSA, BCPS
Associate Professor and Director of Residency & Fellowship Training, University of South Carolina College of Pharmacy; Infectious Diseases PGY2 & Clinical Fellowship Director, Prisma Health Richland

Activity Number

0062-9999-20-089-L01-P
Date: 03/12/20
Time: 02:30 PM - 03:30 PM

CE Hours

1.00
 

 

  • Effect of pharmacist-led educational interventions on proton pump inhibitor de-prescribing in an inpatient psychiatric facility – Anju Balani, PharmD Candidate, Presbyterian College School of Pharmacy
  • Cyclin-dependent kinase 8/19 inhibitors suppress the metastatic growth of secondary tumor cells ex vivo – Stephan Bowe, PharmD Candidate, USC College of Pharmacy
  • Comparative Monte Carlo analysis of cefepime/VNRX-5133 and meropenem/vaborbactam against resistant Gram-negative pathogens – Meghan White, PharmD Candidate, MUSC College of Pharmacy
 
At the completion of this activity, the pharmacist will be able to:
  1. Discuss emerging research outcomes from throughout the state of South Carolina
  2. Recognize novel ideas for research and quality initiative projects in your pharmacy practice areas
  3. Review pivotal results from local investigations across the state of South Carolina

Activity Number

0062-9999-20-090-L04-P
Date: 03/12/20
Time: 04:00 PM - 05:00 PM

CE Hours

1.00
 

 

At the completion of this activity, the pharmacist will be able to:
  1. Recall pharmacy trivia related to pharmacology, pharmacokinetics, pharmacodynamics, pharmacogenomics, clinical pharmacy history, biostatistics, and health outcomes
  2. Summarize clinical knowledge in response to a case vignette using supporting laboratory, physical examination, and medical history information
  3. Discuss numerous drug therapy and specialty areas through response to pharmacotherapy questions

Speaker(s)/Author(s)

P. Brandon Bookstaver, PharmD, FCCP, FIDSA, BCPS
Associate Professor and Director of Residency & Fellowship Training, University of South Carolina College of Pharmacy; Infectious Diseases PGY2 & Clinical Fellowship Director, Prisma Health Richland

Activity Number

0062-9999-20-091-L01-P
Date: 03/12/20
Time: 05:00 PM - 05:30 PM

CE Hours

0.50
 

 

 

At the completion of this activity, the pharmacist will be able to:
  1. Review the history of opioid use and the impact of the current opioid epidemic in the U.S.
  2. Discuss pain management strategies that health care practitioners can use in light of the opioid epidemic
  3. Review the path to opioid use disorder (OUD) and key preventative strategies that everyone can employ to reduce the risk of opioid overdose

Speaker(s)/Author(s)

Doug Furmanek, PharmD, BCCP
Director, Clinical Pharmacy Services, Prisma Health - Upstate

Activity Number

0062-9999-20-095-L08-P
Date: 03/13/20
Time: 08:00 AM - 09:00 AM

CE Hours

1.00
 

 

At the completion of this activity, the pharmacist will be able to:
  1. Evaluate the role of newer, carbapenem-sparing agents for the treatment of resistant Gram-negative bloodstream infections (BSI)
  2. Identify and assess candidates for shorter durations of therapy for BSIs
  3. Evaluate and apply recent literature for oral antibiotics in BSIs

Speaker(s)/Author(s)

Krutika N. Mediwala, PharmD, BCPS, BCIDP
Clinical Pharmacy Specialist – Infectious Diseases/Antimicrobial Stewardship, MUSC Health

Activity Number

0062-9999-20-096-L01-P
Date: 03/13/20
Time: 09:00 AM - 10:00 AM

CE Hours

1.00
 

 

At the completion of this activity, the pharmacist will be able to:
  1. Demonstrate knowledge of Advanced Cardiac Life Support (ACLS) algorithms per the American Heart Association (AHA) guidelines
  2. Discuss the evidence behind interventions in cardiac arrest and determine which interventions are most likely to positively impact patient outcomes
  3. Describe the possible future of cardiac arrest care based on emerging evidence

Speaker(s)/Author(s)

Elizabeth Robinette, PharmD, BCCCP
Trauma Surgical ICU Pharmacy Specialist, McLeod Health

Activity Number

0062-9999-20-097-L01-P
Date: 03/13/20
Time: 10:30 AM - 11:30 AM

CE Hours

1.00
 

 

At the completion of this activity, the pharmacist will be able to:
  1. Describe the mechanisms of action for ascorbic acid, thiamine, and angiotensin II for the treatment of septic shock
  2. List the possible pros and cons of using ascorbic acid, thiamine, and angiotensin II for a patient with septic shock
  3. Design appropriate monitoring parameters when prescribed ascorbic acid, thiamine, and angiotensin II, given a patient in septic shock

Speaker(s)/Author(s)

Carolyn A. Magee, PharmD, BCCCP
Clinical Pharmacy Specialist-Medical Surgical ICU, Medical University of South Carolina

Activity Number

0062-9999-20-098-L01-P
Date: 03/13/20
Time: 11:30 AM - 12:30 PM

CE Hours

1.00
 

 

At the completion of this activity, the pharmacist will be able to:
 
Community-Acquired Pneumonia Duration of Therapy - Rebecca Howell, PharmD, RN
  1. Determine the appropriate duration of therapy for community-acquired pneumonia (CAP)?
  2. Summarize the evidence regarding duration of therapy for CAP
HELLP me! Is this preeclampsia? - Robin Fischer, PharmD
  1. Define gestational hypertension, preeclampsia and HELLP
  2. Identify the most common risk factors for preeclampsia
The Nose Knows: Utilization of the MRSA PCR Nasal Swab in more than just Pneumonia - Jasmine E. Manning, MPH, PharmD
  1. Review current guidelines and literature for the utilization of the MRSA-PCR nasal swab
  2. Identify appropriate non-respiratory related illnesses in which MRSA-PCR nasal swab can be utilized to guide antibiotic therapy

Speaker(s)/Author(s)

Jasmine E. Manning, MPH, PharmD
PGY1 Inpatient Pharmacy Resident, Prisma Health- Richland

Rebecca Howell, PharmD, RN
PGY1 Pharmacy Resident, Spartanburg Regional Healthcare System

Robin Fischer, PharmD
PGY1 Pharmacy Resident, McLeod Regional Medical Center

Activity Number

0062-9999-20-099-L01-P
Date: 03/13/20
Time: 02:30 PM - 03:30 PM

CE Hours

1.00
 

 

At the completion of this activity, the pharmacist will be able to:
 
Clinical Controversies in the Emergent Treatment of Hyperkalemia - Reaghan Erickson, PharmD
  1. Recommend low-dose insulin regimens for high-risk patients with hyperkalemia
  2. Evaluate the potential role of potassium binders in the emergent treatment of hyperkalemia
Worth A Shot?: A Discussion On A Novel Migraine Injectable - Melanie Routhieaux, PharmD, BCPS
  1. Identify the current available preventative migraine treatment options
  2. Evaluate the literature available for erenumab to determine its place in therapy
The Basics of Diabetes Technology: CGMs - Kennedy Gambill, PharmD
  1. Determine the appropriate utilization of continuous glucose monitoring in diabetes care.
Let's Talk about TEG - Hannah Green, PharmD
  1. Discuss thromboelastography (TEG) use and the interpretation of results in the setting of hemorrhage

Speaker(s)/Author(s)

Hannah Green, PharmD
PGY1 Pharmacy Practice Resident , McLeod Regional Medical Center

Kennedy Gambill, PharmD
PGY1 Pharmacy Resident, Spartanburg Medical Center

Melanie Routhieaux, PharmD, BCPS
PGY2 Psychiatric Pharmacy Resident, Columbia VA Health Care System

Reaghan Erickson, PharmD
PGY1 Pharmacy Resident, Spartanburg Medical Center

Activity Number

0062-9999-20-100-L01-P
Date: 03/13/20
Time: 03:45 PM - 04:45 PM

CE Hours

1.00
 

 

At the completion of this activity, the pharmacist will be able to:
  1. Identify drug information topics and resources taught in didactic pharmacy curricula
  2. Recognize common learning theories
  3. Discover methodologies utilized on a successful rotation
  4. Utilize available tools to maintain a current pharmacy knowledge base

Speaker(s)/Author(s)

Christopher S. Wisniewski, PharmD, MSCR, BCPS
Associate Professor, Medical University of South Carolina College of Pharmacy

Activity Number

0062-9999-20-101-L04-P
Date: 03/13/20
Time: 04:45 PM - 05:45 PM

CE Hours

1.00